Compare Ferrari NV (RACE) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ferrari NV vs Revvity Inc — how do they compare? Ferrari NV trades at $409.61 (market cap $70.66B), while Revvity Inc trades at $124.14 (market cap $13.82B). The key difference: Ferrari NV is far larger — about 5.1× Revvity Inc's market cap, and Ferrari NV pays the higher dividend (1.05%). Which is the better fit depends on your goals.
| RACE | RVTY | |
|---|---|---|
Market Cap | $70.66B | $13.82B |
Sector | Consumer Cyclical | Technology |
52-Week High | $504.09 | $130.94 |
52-Week Low | $314.63 | $82.26 |
Enterprise Value | $72.61B | $16.14B |
Dividend Yield | 1.05% | 0.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $405.94, down 0.98% on the day, amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, revenue growth from $5.1B in 2022 to $7.1B in 2025, and robust profitability margins. Recent news highlights a record $40 million auction of its first electric car, reinforcing brand prestige. Analyst consensus is bullish with a $462.67 price target, though technical indicators suggest near-term pressure with support at $402 and resistance at $411.
The outlook remains positive due to Ferrari's pricing power and margin strength, but risks include high valuation multiples and economic sensitivity. Institutional buying and share repurchases provide support, yet investors face volatility from technical bearishness and competitive pressures in the luxury auto sector.
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
